Results for the third quarter 2018 for Medistim ASA

Sales ended at MNOK 77.6 for the quarter (MNOK 77.7), a 2.5 % growth. Sales as of September increased by 4.0 % and ended at MOK 228.0 (MNOK 219.2). Revenue from own products showed a currency neutral decline of 0.4 % for the quarter and a currency neutral growth of 4.2 % YTD. Operating profit (EBIT) for the quarter ended at MNOK 14.5 (MNOK 19.4). Operating profit as of September ended at MNOK 46.2 (MNOK 49.1). There was a solid growth in system sales that creates the basis for future probe revenue. Number units year to date increases with 25.0 %. The final results from the REQUEST study was presented during EACTS in Milano. The study confirms the value of the combined use of flow and imaging.